Ireland
--:--IST
Priya Life Science Regulatory
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 11 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
977Linked to a medicine page here

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
  • Recommended: the NHS in England should fund it for the use it is licensed for.
  • Optimised: recommended, but for a narrower group of patients than the licence covers.
  • Cancer Drugs Fund / Innovative Medicines Fund: funded for a limited period while more evidence is collected.
  • Only in research: to be used only as part of a study.
  • Not recommended: NICE decided the NHS should not fund it for this use.
  • Terminated: the company did not send evidence, so NICE could not make a recommendation.

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Appraisals matching “Pembrolizumab”

42 appraisals, newest first
AppraisalMedicine pageNICE recommendationPublishedStatus
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer
NICE TA1177
PembrolizumabRecommended14 Jul 2026Current
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma
NICE TA1145
PembrolizumabRecommended21 Apr 2026Current
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)
NICE TA1125
PembrolizumabTerminated (no company submission)27 Jan 2026Current
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable
NICE TA1097
Enfortumab VedotinRecommended11 Sep 2025Current
Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer
NICE TA1092
PembrolizumabRecommended27 Aug 2025Current
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer
NICE TA1037
PembrolizumabRecommended5 Feb 2025Current
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
NICE TA1017
PembrolizumabRecommended20 Nov 2024Current
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma
NICE TA997
PembrolizumabRecommended29 Aug 2024Current
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma
NICE TA983
PembrolizumabNot recommended12 Jun 2024Current
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over
NICE TA967
PembrolizumabOptimised1 May 2024Current
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)
NICE TA966
PembrolizumabTerminated (no company submission)24 Apr 2024Current
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
NICE TA939
PembrolizumabOptimised13 Dec 2023Current
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
NICE TA914
PembrolizumabOptimised20 Sep 2023Current
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
NICE TA904
PembrolizumabRecommended21 Jun 2023Current
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
NICE TA885
PembrolizumabRecommended (Cancer Drugs Fund)3 May 2023Replaced by TA939
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma
NICE TA858
Lenvatinib, PembrolizumabOptimised11 Jan 2023Current
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer
NICE TA851
PembrolizumabRecommended14 Dec 2022Current
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma
NICE TA837
PembrolizumabRecommended26 Oct 2022Current
Pembrolizumab for adjuvant treatment of renal cell carcinoma
NICE TA830
PembrolizumabRecommended19 Oct 2022Current
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
NICE TA801
PembrolizumabOptimised29 Jun 2022Current
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies
NICE TA772
PembrolizumabRecommended23 Feb 2022Current
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA770
PembrolizumabOptimised9 Feb 2022Current
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma
NICE TA766
PembrolizumabRecommended2 Feb 2022Current
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
NICE TA737
PembrolizumabRecommended20 Oct 2021
Updated 29 Aug 2024
Current
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
NICE TA709
PembrolizumabOptimised23 Jun 2021Current
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA692
PembrolizumabNot recommended28 Apr 2021Current
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
NICE TA683
PembrolizumabOptimised10 Mar 2021Current
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)
NICE TA674
PembrolizumabTerminated (no company submission)17 Feb 2021Current
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
NICE TA661
PembrolizumabOptimised25 Nov 2020Current
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma
NICE TA650
PembrolizumabNot recommended30 Sep 2020Current
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA600
PembrolizumabRecommended (Cancer Drugs Fund)11 Sep 2019Current
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)
NICE TA570
PembrolizumabTerminated (no company submission)20 Mar 2019Current
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
NICE TA557
PembrolizumabOptimised (Cancer Drugs Fund)10 Jan 2019Replaced by TA683
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
NICE TA553
PembrolizumabRecommended (Cancer Drugs Fund)19 Dec 2018Current
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA540
PembrolizumabOptimised (Cancer Drugs Fund)3 Sep 2018
Updated 1 May 2024
Current
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA531
PembrolizumabOptimised18 Jul 2018Current
Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA522
PembrolizumabRecommended (Cancer Drugs Fund)13 Jun 2018Current
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA519
PembrolizumabRecommended (Cancer Drugs Fund)25 Apr 2018Replaced by TA692
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA447
PembrolizumabOptimised (Cancer Drugs Fund)28 Jun 2017Current
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
NICE TA428
PembrolizumabOptimised11 Jan 2017
Updated 12 Sep 2017
Current
Pembrolizumab for advanced melanoma not previously treated with ipilimumab
NICE TA366
PembrolizumabRecommended25 Nov 2015
Updated 12 Sep 2017
Current
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
NICE TA357
PembrolizumabRecommended7 Oct 2015
Updated 12 Sep 2017
Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 11 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.